# US 2013/0274258 A1 · Carbazole and carboline derivatives, and preparation and therapeutic applications thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274258 A1
- Document ID: US20130274258A1
- Status: Published application
- Kind: A1
- Application number: 13/883,380
- Filed: 2011-11-03
- Published: 2013-10-17
- Earliest claimed: 2010-11-03
- Assignees: Philip Morris Products S.A.
- Inventors: Stephane Demotz; Gerhard Lang; Damian McHugh; Axel Teichert; Fernando Goffman; Paul M. Doyle; Paul M. Blaney; Raymond Fisher; Andrew Smith; Emma L. Blaney; Simon Foster
- Web page: https://patentgrep.com/patent/US20130274258A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 33/00: Antiparasitic agents
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of general formula (I), wherein A, Y, R1 and R2 are defined herein are useful in the treatment or prevention of proliferative diseases including cancer or infectious or parasitic diseases.

## Claims

### Claim 1

A compound of general formula (I):
wherein
A is CH, N or NO,
Y is H, methyl, ethyl or linear or branched lower alkyl with up to 4 carbon atoms, —CH2—O—C(═O)NH(lower alkyl) or —CH2—O—PO3H2,
R1 is aryl or heteroaryl selected from nitrogen containing compounds and oxygen containing compounds optionally substituted by up to four substituents independently selected from:
1. halo,
2. C1-C6 alkyl,
3. C1-C6 haloalkyl,
4. C1-C6 alkoxy, (C1-C4 alkylene)OR3
5. C1-C6 haloalkoxy,
6. NHR3, (C1-C4 alkylene)NHR3, (C1-C4 alkylene)NR3R4,
7. NHC(O)R3, (C1-C4 alkylene)NHC(O)(C1-C6 alkyl),
8. C(O)NR3R4, (C1-C4 alkylene)C(O)NR3R4;
9. C(O)R3, (C1-C4 alkylene)C(O)R3;
10. C(O)O(C1-C6 alkyl), (C1-C4 alkylene)C(O)O(C1-C6 alkyl),
11. OC(O)(C1-C6 alkyl), (C1-C4 alkylene)OC(O)(C1-C6 alkyl),
12. OH, (C1-C4 alkylene)OH,
13. CN, (C1-C4 alkylene)CN,
14. aryl or heteroaryl selected from nitrogen containing compounds and oxygen containing compounds optionally substituted,
15. non-aromatic heterocyclic groups selected from nitrogen containing compounds, oxygen containing compounds and nitrogen and oxygen containing compounds optionally substituted,
16. NHC(O)NR3R4, (C1-C4 alkylene)NHC(O)NR3R4,
17. O(C1-C4 alkylene)OR3, (C1-C4 alkylene)O(C1-C4 alkylene)OR3,
18. NHS(O2)R3, (C1-C4 alkylene)NHS(O2)R3,
19. S(O2)NH2, S(O2)NHR3, S(O2)NR3R4,
20. S(O2)NH(C1-C4 alkylene)OH, S(O2)NH(C1-C4 alkylene)OR3,
21. C(O)NH(C1-C4 alkylene)OH, C(O)NH(C1-C4 alkylene)OR3,
wherein each R3 and each R4 is independently H or C1-C6 alkyl; and
wherein any of the suitable substituents for R1 described above may be substituted with one or more chloro or fluoro substitutents;
R2 is linear or branched C1-C6 alkyl optionally substituted with F or Cl;
or a pharmaceutically acceptable salt or solvate thereof;
provided that
if R1 is a phenyl group, it is not substituted by any of the substituents 1 to 12 or 14 to 21 at the 4-position,
if R1 is a phenyl group, it is not substituted by any of the substituents 2 to 21 at the 2-position
if R1 is an aryl, it is not a naphthalenyl group, anthracenyl or phenanthrenyl group,
if R1 is an heteroaryl selected from nitrogen containing compounds, it is not a pyrimidinyl or a pyridazinyl group.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein R2 is linear or branched C1-C4 alkyl optionally substituted with F or Cl.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein A is nitrogen (N).

### Claim 4 (depends on 1)

A compound according to claim 1, wherein R1 is selected from the group consisting of phenyl, pyridyl, benzopyridyl, pyrrolyl, tetrazolyl, indolyl, indolinyl, furanyl, benzofuranyl, dihydrobenzofuranyl, dihydrobenzopyranyl, and benzodioxolyl, optionally substituted as described above.

### Claim 5 (depends on 4)

A compound according to claim 4, wherein R1 is an unsubstituted or substituted phenyl group.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein R1 is unsubstituted or has 1 to 4 substituents selected from the group consisting of:
halo,
C1-C4 alkyl,
C1-C4 haloalkyl,
C1-C4 alkoxy, (C1-C2 alkylene)OR3,
C1-C4 haloalkoxy,
NHR5, (C1-C2 alkylene)NHR5, (C1-C2 alkylene)NR5R6,
NHC(O)R5, (C1-C2 alkylene)NHC(O)(C1-C4 alkyl),
C(O)NR5R6, (C1-C2 alkylene)C(O)NR5R6;
C(O)R5; (C1-C2 alkylene)C(O)R5;
C(O)O(C1-C4 alkyl), (C1-C2 alkylene)C(O)O(C1-C4 alkyl),
OC(O)(C1-C4 alkyl), (C1-C2 alkylene)OC(O)(C1-C4 alkyl),
OH, (C1-C2 alkylene)OH,
CN, (C1-C2 alkylene)CN,
aryl or heteroaryl selected from nitrogen containing compounds and oxygen containing compounds optionally substituted,
non-aromatic heterocyclic groups selected from nitrogen containing compounds, oxygen containing compounds and nitrogen and oxygen containing compounds optionally substituted,
NHC(O)NR5R6, (C1-C2 alkylene)NHC(O)NR5R6,
O(C1-C2 alkylene)OR5, (C1-C2 alkylene)O(C1-C2 alkylene)OR5,
NHS(O2)R5, (C1-C2 alkylene)NHS(O2)R5,
S(O2)NH2, S(O2)NHR5, S(O2)NR5R6,
S(O2)NH(C1-C2 alkylene)OH, S(O2)NH(C1-C2 alkylene)OR5, and
C(O)NH(C1-C2 alkylene)OH, C(O)NH(C1-C2 alkylene)OR3,
wherein each R5 and each R6 is independently H or C1-C4 alkyl, and
wherein any of the suitable substituents for R1 described above is optionally substituted with one or more chloro or fluoro substitutents.

### Claim 7 (depends on 1)

A compound according to claim 1 selected from:
6-phenyl-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-chlorophenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3,5-dichlorophenyl)-1-methyl-9H-pyrido[3,4-b]indole,
6-(2-fluorophenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-fluorophenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-(trifluoromethyl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(5-ethoxy-2-fluorophenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3,5-dimethylphenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-methoxyphenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-(aminomethyl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-(acetamidomethyl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-aminocarbonylphenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-acetylphenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-methoxycarbonylphenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-(acetoxymethyl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3,5-bis(acetoxymethyl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-hydroxyphenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-hydroxymethylphenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-(1-hydroxyethyl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3,5-bis(hydroxymethyl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-cyanophenyl)-1-methyl-9H-pyrido[3,4-b]indole,
6-(4-cyanophenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-cyanomethylphenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(5-cyano-2-fluorophenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(pyridine-3-yl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(1H-indol-5-yl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(((2H-tetrazol-5-yl)methyl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(5-methylfuran-2-yl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(2,3-dihydrobenzofuran-5-yl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(benzo[d][1,3]dioxol-5-yl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(5-formylfuran-2-yl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(5-hydroxymethylfuran-2-yl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-aminophenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-formamidophenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-aminocarbonylphenyl)-1-ethyl-9H-pyrido[3,4-b]indole;
6-(2,3-dihydrobenzofuran-5-yl)-1-trifluoromethyl-9H-pyrido[3,4-b]indole;
6-(2,3-dihydrobenzofuran-5-yl)-1-ethyl-9H-pyrido[3,4-b]indole;
6-(2,3-dihydrobenzofuran-5-yl)-1-propyl-9H-pyrido[3,4-b]indole;
6-(2,3-dihydrobenzofuran-5-yl)-1-isopropyl-9H-pyrido[3,4-b]indole;
6-(3-(methoxymethyl)phenyl)-1-ethyl-9H-pyrido[3,4-b]indole;
1-ethyl-3-(1-methyl-9H-pyrido[3,4-b]indol-6-yl)benzyl)urea;
N,N-dimethyl-1-(3-(1-methyl-9H-pyrido[3,4-b]indol-6-yl)phenyl)methanamine;
6-(3-((2-methoxyethoxy)methyl)phenyl) 1-ethyl-9H-pyrido[3,4-b]indole;
N-(3-(1-ethyl-9H-pyrido[3,4-b]indol-6-yl)phenyl)methanesulfonamide;
N-(1-methyl-9H-pyrido[3,4-b]indol-6-yl)benzyl)methanesulfonamide;
3-(1-methyl-9H-pyrido[3,4-b]indol-6-yl)benzenesulfonamide;
N-(2-hydroxyethyl)-3-(1-methyl-9H-pyrido[3,4-b]indol-6-yl)benzenesulfonamide;
N-(2-hydroxyethyl)-3-(1-methyl-9H-pyrido[3,4-b]indol-6-yl)benzamide;
4-methyl-N-(1-methyl-9H-pyrido[3,4-b]indol-6-yl)benzyl)piperazine-1-carboxamide;
3-(1-ethyl-9-methyl-9H-pyrido[3,4-b]indol-6-yl)benzamide;
6-(2,3-dihydrobenzofuran-5-yl)-1,9-dimethyl-9H-pyrido[3,4-b]indole;
N-(3-(1-ethyl-9H-pyrido[3,4-b]indol-6-yl)phenyl)acetamide;
6-(5-methoxypyridin-3-yl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(chroman-6-yl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3-(furan-2-yl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole;
4-(1-methyl-9H-pyrido[3,4-b]indol-6-yl)benzyl)morpholine;
6-(3-((4-methylpiperazin-1-yl)methyl)phenyl)-1-methyl 9H-pyrido[3,4-b]indole;
6-(2,3-dihydrobenzofuran-5-yl)-1-methyl-9H-carbazole;
6-(3-(1H-pyrazol-1-yl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole;
6-(3,5-dichlorophenyl)-1-methyl-9H-pyrido[3,4-b]indole 2-oxide;
and pharmaceutically acceptable salts or solvates thereof.

### Claim 8 (depends on 1)

A medicament comprising a compound according to claim 1.

### Claim 9 (depends on 1)

A method comprising administering a compound according to claim 1 to a subject in need thereof for the treatment or prevention of a proliferative disorder or a parasitic disease.

### Claim 10 (depends on 1)

A method comprising contacting tubulin with a compound according to claim 1 for modulating tubulin polymerization.

### Claim 11 (depends on 1)

A method comprising administering a compound according to claim 1 to a subject in need thereof for use in treatment or prevention of a cancerous disease or a parasitic disease.

### Claim 12 (depends on 1)

A pharmaceutical or veterinary composition comprising a compound according to claim 1 together with a pharmaceutically or veterinarily acceptable carrier.

### Claim 13 (depends on 1)

A product comprising a compound according to claim 1 and one or more of additional therapeutic agents as a combined preparation for simultaneous, separate or sequential use in the treatment of a proliferative disorder or a parasitic disease.

### Claim 14 (depends on 1)

A process for the preparation of a compound according to claim 1, the process comprising reacting a compound of the formula:
wherein A is CH or N, Y is H, methyl or ethyl and R2 are as defined for general formula (I) and X is a leaving group;
with a compound of the formula:
R1—B(OH)2 or the corresponding ester,
where R1 is as defined for general formula (I).

### Claim 15 (depends on 14)

The process of claim 14, further comprising reacting a product of the process of claim 14 to form a compound of general formula (I).

### Claim 16 (depends on 5)

A compound according to claim 5, wherein R1 is a phenyl group substituted at least at the 3-position or substituted at least at the 3- and the 5-position.

### Claim 17 (depends on 16)

A compound according to claim 16, wherein R1 is a phenyl group substituted with a substituent selected from the group consisting of 3-pyridyl, 2,3-benzofuran-5-yl, 5-substituted furan-2-yl, benzo[d][1,3]dioxo-5-yl and 1H-indol-5-yl.

### Claim 18 (depends on 5)

A compound according to claim 5, wherein R1 is a phenyl group substituted with a substituent selected from the group consisting of 3-pyridyl, 2,3-benzofuran-5-yl, 5-substituted furan-2-yl, benzo[d][1,3]dioxo-5-yl and 1H-indol-5-yl.

### Claim 19 (depends on 2)

A compound according to claim 2, wherein A is nitrogen (N).

### Claim 20 (depends on 19)

A compound according to claim 19, wherein R1 is phenyl, pyridyl, benzopyridyl, pyrrolyl, tetrazolyl, indolyl, indolinyl, furanyl, benzofuranyl, dihydrobenzofuranyl, dihydrobenzopyranyl, and benzodioxolyl, optionally substituted as described above, any of which is optionally substituted.

### Claim 21 (depends on 19)

A compound according to claim 19, wherein R1 is an unsubstituted or substituted phenyl group.

### Claim 22 (depends on 21)

A compound according to claim 21, wherein R1 is a phenyl group substituted at least at the 3-position or substituted at least at the 3- and the 5-position.

### Claim 23 (depends on 22)

A compound according to claim 22, wherein R1 is a phenyl group substituted with a substituent selected from the group consisting of 3-pyridyl, 2,3-benzofuran-5-yl, 5-substituted furan-2-yl, benzo[d][1,3]dioxo-5-yl and 1H-indol-5-yl.

### Claim 24 (depends on 21)

A compound according to claim 21, wherein R1 is a phenyl group substituted with a substituent selected from the group consisting of 3-pyridyl, 2,3-benzofuran-5-yl, 5-substituted furan-2-yl, benzo[d][1,3]dioxo-5-yl and 1H-indol-5-yl.

### Claim 25

A compound according 19, wherein R1 is unsubstituted or has 1 to 4 substituents selected from the group consisting of:
halo,
C1-C4 alkyl,
C1-C4 haloalkyl,
C1-C4 alkoxy, (C1-C2 alkylene)OR3,
C1-C4 haloalkoxy,
NHR5, (C1-C2 alkylene)NHR5, (C1-C2 alkylene)NR5R6,
NHC(O)R5, (C1-C2 alkylene)NHC(O)(C1-C4 alkyl),
C(O)NR5R6, (C1-C2 alkylene)C(O)NR5R6;
C(O)R5; (C1-C2 alkylene)C(O)R5;
C(O)O(C1-C4 alkyl), (C1-C2 alkylene)C(O)O(C1-C4 alkyl),
OC(O)(C1-C4 alkyl), (C1-C2 alkylene)OC(O)(C1-C4 alkyl),
OH, (C1-C2 alkylene)OH,
CN, (C1-C2 alkylene)CN, or
aryl or heteroaryl selected from nitrogen containing compounds and oxygen containing compounds optionally substituted,
non-aromatic heterocyclic groups selected from nitrogen containing compounds, oxygen containing compounds and nitrogen and oxygen containing compounds optionally substituted,
NHC(O)NR5R6, (C1-C2 alkylene)NHC(O)NR5R6,
O(C1-C2 alkylene)OR5, (C1-C2 alkylene)O(C1-C2 alkylene)OR5,
NHS(O2)R5, (C1-C2 alkylene)NHS(O2)R5,
S(O2)NH2, S(O2)NHR5, S(O2)NR5R6,
S(O2)NH(C1-C2 alkylene)OH, S(O2)NH(C1-C2 alkylene)OR5,
C(O)NH(C1-C2 alkylene)OH, C(O)NH(C1-C2 alkylene)OR3,
wherein each R5 and each R6 is independently H or C1-C4 alkyl, and
wherein any of the suitable substituents for R1 described above is optionally substituted with one or more chloro or fluoro substitutents.

### Claim 26 (depends on 3)

A compound according to claim 3, wherein R1 is phenyl, pyridyl, benzopyridyl, pyrrolyl, tetrazolyl, indolyl, indolinyl, furanyl, benzofuranyl, dihydrobenzofuranyl, dihydrobenzopyranyl, and benzodioxolyl, optionally substituted as described above, any of which is optionally substituted.

### Claim 27 (depends on 26)

A compound according to claim 26, wherein R1 is an unsubstituted or substituted phenyl group.

### Claim 28 (depends on 27)

A compound according to claim 27, wherein R1 is a phenyl group substituted at least at the 3-position or substituted at least at the 3- and the 5-position.

### Claim 29 (depends on 28)

A compound according to claim 28, wherein R1 is a phenyl group substituted with a substituent selected from the group consisting of 3-pyridyl, 2,3-benzofuran-5-yl, 5-substituted furan-2-yl, benzo[d][1,3]dioxo-5-yl and 1H-indol-5-yl.

### Claim 30 (depends on 27)

A compound according to claim 27, wherein R1 is a phenyl group substituted with a substituent selected from the group consisting of 3-pyridyl, 2,3-benzofuran-5-yl, 5-substituted furan-2-yl, benzo[d][1,3]dioxo-5-yl and 1H-indol-5-yl.

### Claim 31

A compound according 26, wherein R1 is unsubstituted or has 1 to 4 substituents selected from the group consisting of:
halo,
C1-C4 alkyl,
C1-C4 haloalkyl,
C1-C4 alkoxy, (C1-C2 alkylene)OR3,
C1-C4 haloalkoxy,
NHR5, (C1-C2 alkylene)NHR5, (C1-C2 alkylene)NR5R6,
NHC(O)R5, (C1-C2 alkylene)NHC(O)(C1-C4 alkyl),
C(O)NR5R6, (C1-C2 alkylene)C(O)NR5R6;
C(O)R5; (C1-C2 alkylene)C(O)R5;
C(O)O(C1-C4 alkyl), (C1-C2 alkylene)C(O)O(C1-C4 alkyl),
OC(O)(C1-C4 alkyl), (C1-C2 alkylene)OC(O)(C1-C4 alkyl),
OH, (C1-C2 alkylene)OH,
CN, (C1-C2 alkylene)CN, or
aryl or heteroaryl selected from nitrogen containing compounds and oxygen containing compounds optionally substituted,
non-aromatic heterocyclic groups selected from nitrogen containing compounds, oxygen containing compounds and nitrogen and oxygen containing compounds optionally substituted,
NHC(O)NR5R6, (C1-C2 alkylene)NHC(O)NR5R6,
O(C1-C2 alkylene)OR5, (C1-C2 alkylene)O(C1-C2 alkylene)OR5,
NHS(O2)R5, (C1-C2 alkylene)NHS(O2)R5,
S(O2)NH2, S(O2)NHR5, S(O2)NR5R6,
S(O2)NH(C1-C2 alkylene)OH, S(O2)NH(C1-C2 alkylene)OR5,
C(O)NH(C1-C2 alkylene)OH, C(O)NH(C1-C2 alkylene)OR3,
wherein each R5 and each R6 is independently H or C1-C4 alkyl, and
wherein any of the suitable substituents for R1 described above is optionally substituted with one or more chloro or fluoro substitutents.

### Claim 32 (depends on 1)

An intermediate in the synthesis of a medicament comprising a compound according to claim 1.
